Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
BMY.RT was delisted on the 31st of December, 2020.
583 hedge funds and large institutions have $1.89B invested in Bristol-Myers Squibb Company Contingent Value Rights in 2020 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 92 increasing their positions, 214 reducing their positions, and 61 closing their positions.
1,865% more call options, than puts
Call options by funds: $24.4M | Put options by funds: $1.24M
10% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 61
0% more funds holding
Funds holding: 581 → 583 (+2)
7% less capital invested
Capital invested by funds: $2.03B → $1.89B (-$138M)
8% less funds holding in top 10
Funds holding in top 10: 12 → 11 (-1)
57% less repeat investments, than reductions
Existing positions increased: 92 | Existing positions reduced: 214
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$32.5M |
| 2 |
HI
HBK Investments
Dallas,
Texas
|
+$21.6M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$20.9M |
| 4 |
DKCM
Davidson Kempner Capital Management
New York
|
+$20.5M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$45.4M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$16.3M |
| 3 |
JG
Jefferies Group
New York
|
-$13.5M |
| 4 |
HM
HealthCor Management
New York
|
-$13.4M |
| 5 |
Renaissance Technologies
New York
|
-$12.2M |
BMY.RT Hedge Fund Activity: Q2 2020 in Review
583 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) for Q2 2020, worth a combined $1.89B — down 6.8% from $2.03B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new BMY.RT positions and 61 closed out — a net gain of 6 holders — while 92 added to existing stakes and 214 trimmed.
The largest buyer was Farallon Capital Management, adding an estimated $32.5M. The largest seller was Citadel Advisors, cutting an estimated $45.4M.
- 583 institutional investors held Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) as of Q2 2020, up from 581 in Q1 2020.
- Funds reported $1.89B of Bristol-Myers Squibb Company Contingent Value Rights stock for Q2 2020, down 6.8% quarter-over-quarter.
- 67 funds opened new Bristol-Myers Squibb Company Contingent Value Rights positions in Q2 2020 and 61 closed out, a net change of +6 holders.
- The largest Bristol-Myers Squibb Company Contingent Value Rights buyer in Q2 2020 was Farallon Capital Management, an estimated $32.5M added.
- The largest Bristol-Myers Squibb Company Contingent Value Rights seller in Q2 2020 was Citadel Advisors, an estimated $45.4M sold.
Based on aggregated 13F filings for Q2 2020.